ArticlePediatric radiology2026
Quantitative magnetic resonance imaging radiomics predicts photoreceptorness status in retinoblastoma.
Article in Pediatric radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMolecular characteristics of retinoblastoma cannot be assessed before treatment because tumor biopsy is contraindicated. Photoreceptorness reflects photoreceptor-related gene expression and tumor differentiation. Non-invasive imaging biomarkers that capture this biology are therefore needed.
objectiveTo evaluate whether quantitative radiomics derived from pretreatment magnetic resonance imaging can predict loss of photoreceptorness in retinoblastoma and validate this approach in an independent cohort. MATERIALS AND
methodsIn this retrospective multicenter study, patients with retinoblastoma who underwent primary enucleation and had both pretreatment T2-weighted magnetic resonance imaging and genome-wide messenger RNA expression data were included. Tumors in the highest and lowest photoreceptorness quartiles were analyzed. Whole-tumor segmentations were used to extract radiomic features with PyRadiomics. Multiple machine-learning pipelines were evaluated using repeated stratified cross-validation, and the best-performing model was tested in an independent cohort.
resultsForty-five patients (median age, 18 months [range, 2-70], 18 female) were included: 29 in the training cohort and 16 in the independent testing cohort. The best-performing model used recursive feature elimination with a random forest classifier and achieved a mean cross-validated area under the receiver operating characteristic curve of 0.83 in the training cohort. In the independent testing cohort, the model achieved an area under the receiver operating characteristic curve of 0.81 (95% confidence interval, 0.54-1.00) for predicting loss of photoreceptorness.
conclusionQuantitative magnetic resonance imaging radiomics showed preliminary moderate-to-good discriminatory performance for non-invasively predicting photoreceptorness status in retinoblastoma. These proof-of-concept findings suggest that radiomics may capture imaging features related to molecular tumor differentiation and could support the development of personalized treatment strategies.
Indexed as
Identifiers
42554833What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.